首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

2076216

化療引起的血小板減少性疾病治療市場：依藥物類別、給藥途徑、通路和地區分類

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，化療引起的血小板減少性疾病治療市場規模將達到 17.758 億美元，到 2033 年將達到 25.322 億美元。預計從 2026 年到 2033 年，該市場將以 5.2% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	17.758億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	5.20%	2033年市場規模預測：	25.322億美元

血小板減少性疾病是指體內血小板數量減少的疾病。血小板是無色血細胞，有助於血液凝固。血小板減少性疾病在癌症患者中很常見。化療引起的血小板血小板減少性疾病的發生情況因人而異，取決於所使用的化療。每種化療藥物引起血小板減少性疾病的機轉都不同。大多數化療引起的血小板減少性疾病是由Gemcitabine和含鉑類藥物類化療方案引起的。烷化劑會影響造血幹細胞，Cyclophosphamide會影響晚期大核前驅細胞，Bortezomib會抑制血小板從大核細胞中釋放，一些治療方法也會促進血小板凋亡。血小板減少性疾病也可能由感染疾病或與癌症治療相關的藥物不良反應所引起。化療血小板減少性疾病可能造成嚴重危害，因為它會導致化療延遲、化療藥物劑量減少、醫療費用增加以及出血。

市場動態

隨著癌症患者數量的增加，化療的數量預計將大幅成長，這將推動歐洲化療引起的血小板減少性疾病（CIT）市場的發展。例如，根據世界衛生組織（WHO）的數據，每年新增癌症病例超過370萬例，死亡人數達190萬人。 2012年，癌症是歐洲第二大死因和殘疾原因。在全球範圍內，癌症導致820萬人死亡。目前，歐盟尚無核准的化療引起的血小板減少性疾病（CIT）治療方案。

然而，由於化療引起的血小板減少性疾病治療臨床試驗的失敗，預計全球化療引起的血小板減少性疾病治療市場在預測期內的成長將受到阻礙。例如，2020年10月，瑞典Orphan Biovitrum AB公司發表了口服血小板生成素（TPO）受體促效劑Avatrombopag（Doptelet）治療固體癌合併化療引起的血小板減少性疾病和化療劑量減重15%或以上，但這些終點均未達到，也未證實血小板減少性疾病對化療引起的血小板減少症有效。

本次考試的主要特點：

本研究確定了各個細分市場的潛在商機，並為該市場說明了一個有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及領先企業採取的競爭策略。
本研究根據以下參數對全球化療引起的血小板減少性疾病治療市場的主要參與者進行了分析：公司概況、財務績效、產品系列、地理企業發展、分銷策略、關鍵發展和整體策略。
本報告提供的見解將使企業負責人和經營團隊能夠就未來的產品發布、政府措施、技術升級、市場擴張和行銷策略做出明智的決策。
這份「全球化療引起的血小板減少性疾病治療市場」報告針對該行業的各種利益相關者，包括投資者、產品製造商、經銷商、透析市場供應商、研究和諮詢相關人員、新參與企業和金融分析師。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
公司簡介
- Amgen, Inc.
- Novartis AG
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Jiangsu HengRui Medicine Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan NV

第9章

參考
調查方法

簡介目錄

Product Code: CMI4332

Chemotherapy Induced Thrombocytopenia Therapeutics Market is estimated to be valued at USD 1,775.8 Mn in 2026 and is expected to reach USD 2,532.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,775.8 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.20%	2033 Value Projection:	USD 2,532.2 Mn

Thrombocytopenia is a condition in which blood platelets are low in person's body. Thrombocytes are colourless blood cells that help blood clot. Thrombocytopenia is common in cancer patients. The occurrence of chemotherapy-induced thrombocytopenia varies from person to person depending on the treatment used. Each chemotherapy agent differs in how it causes thrombocytopenia. Mostly chemotherapy-induced thrombocytopenia are caused by the gemcitabine-and platinum-based regimens used in chemotherapy. Alkylating agents affect stem cells, cyclophosphamide affects later megakaryocyte progenitors, bortezomib prevents platelet release from megakaryocytes, and some treatments promote platelet apoptosis. Thrombocytopenia can also occur with any infection or adverse drug reaction associated with cancer treatment. Chemotherapy-induced therapy can be particularly harmful, as it can delay chemotherapy, decrease the dose of chemotherapy drugs, increase medical expenses, and can cause induced bleeding.

Market Dynamics

The increasing number of cancer cases is expected to surge the number of chemotherapy procedures, and this is expected to drive the Euopean chemotherapy-induced thrombocytopenia therapeutics market. For instance, according to the World health Organization (WHO), over 3.7 million new cancer cases and 1.9 million death occur each year, and cancer represents the second most important cause of death and morbidity in 2012 in Europe, on a global scale, cancer accounted for 8.2 million deaths Currently, there are no approved treatments available for (chemotherapy-induced thrombocytopenia) CIT in the European Union.

However, growth of the global chemotherapy-induced thrombocytopenia therapeutics market is expected to be hampered over the forecast period, owing to discontinuation of clinical trials due to failure of chemotherapy-induced thrombocytopenia therapeutics. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia.

Key features of the study:

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Amgen, Inc., Novartis AG., Pfizer Inc., LLC, Swedish Orphan Biovitrum AB., Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for dialysis market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Thrombopoietin Receptor Agonists
Thrombopoietic Agents
- Others
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Injectable
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmaciesa
Retail Pharmacies
Online Pharmacies
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
- By Drug Class:
  - Thrombopoietin Receptor Agonists
  - Thrombopoietic Agents
  - Others
- By Route of Administration:
  - Oral
  - Injectable
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Europe
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
- By Drug Class:
  - Thrombopoietin Receptor Agonists
  - Thrombopoietic Agents
  - Others
- By Route of Administration:
  - Oral
  - Injectable
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Asia Pacific
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
- By Drug Class:
  - Thrombopoietin Receptor Agonists
  - Thrombopoietic Agents
  - Others
- By Route of Administration:
  - Oral
  - Injectable
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- By Drug Class:
  - Thrombopoietin Receptor Agonists
  - Thrombopoietic Agents
  - Others
- By Route of Administration:
  - Oral
  - Injectable
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
- By Drug Class:
  - Thrombopoietin Receptor Agonists
  - Thrombopoietic Agents
  - Others
- By Route of Administration:
  - Oral
  - Injectable
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
- By Drug Class:
  - Thrombopoietin Receptor Agonists
  - Thrombopoietic Agents
  - Others
- By Route of Administration:
  - Oral
  - Injectable
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Company Profiles
Amgen, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Novartis AG
Pfizer Inc.
Swedish Orphan Biovitrum AB
Jiangsu HengRui Medicine Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trend
Key Developments
Regulatory Scenario
PEST Analysis
Pipeline Analysis
Acquisition and Collaboration Scenario

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- Amgen, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Swedish Orphan Biovitrum AB
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Jiangsu HengRui Medicine Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

血小板減少性疾病市場規模、佔有率和成長分析：按疾病、療法、藥物類別、給藥途徑、最終用戶、患者群體、分銷管道和地區分類－2026-2033年產業預測

FAQ

化療引起的血小板減少性疾病治療市場：依藥物類別、給藥途徑、通路和地區分類

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

市場動態

本次考試的主要特點：

目錄

第1章：研究目標與前提條件

第2章市場展望

第3章：市場動態、監管與趨勢分析

第4章全球化療誘發血小板減少性疾病症療法市場：依藥物類別分類，2021-2033年

第5章全球化療誘導血小板減少性疾病症療法市場：依給藥途徑分類，2021-2033年

第6章全球化療誘發血小板減少性疾病症療法市場：依通路分類，2021-2033年

第7章全球化療誘發血小板減少性疾病症療法市場：依地區分類，2021-2033年

第8章競爭情勢

第9章

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2021 - 2033, (US$ Mn)

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2021 - 2033, (US$ Mn)

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2021 - 2033, (US$ Mn)

8. Competitive Landscape

9. Section

化療引起的血小板減少性疾病治療市場：依藥物類別、給藥途徑、通路和地區分類

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

市場動態

本次考試的主要特點：

目錄

第1章：研究目標與前提條件

第2章 市場展望

第3章：市場動態、監管與趨勢分析

第4章 全球化療誘發血小板減少性疾病症療法市場：依藥物類別分類，2021-2033年

第5章 全球化療誘導血小板減少性疾病症療法市場：依給藥途徑分類，2021-2033年

第6章 全球化療誘發血小板減少性疾病症療法市場：依通路分類，2021-2033年

第7章 全球化療誘發血小板減少性疾病症療法市場：依地區分類，2021-2033年

第8章 競爭情勢

第9章

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2021 - 2033, (US$ Mn)

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2021 - 2033, (US$ Mn)

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2021 - 2033, (US$ Mn)

8. Competitive Landscape

9. Section

第2章市場展望

第4章全球化療誘發血小板減少性疾病症療法市場：依藥物類別分類，2021-2033年

第5章全球化療誘導血小板減少性疾病症療法市場：依給藥途徑分類，2021-2033年

第6章全球化療誘發血小板減少性疾病症療法市場：依通路分類，2021-2033年

第7章全球化療誘發血小板減少性疾病症療法市場：依地區分類，2021-2033年

第8章競爭情勢